Brown 2013.

Methods	FLUOXETINE Randomized controlled trial Setting: clinic, USA Recruitment: community volunteers
Participants	216 smokers with elevated depressive symptoms (CES‐D score ≥ 6) smoking ≥ 10 cpd. 38.4% F, av age 46, av cpd 21, mean FTND 5.6, mean CES‐D 11.4
Interventions	1. 10 weeks of 20 mg fluoxetine (beginning 2 weeks prior to TQD) 2. 16 weeks of 20 mg fluoxetine (beginning 8 weeks prior to TQD) 3. Control (no placebo) All arms: nicotine patch for 8 weeks starting on TQD (21 mg/day for 4 weeks, 14mg/day for 2 weeks, 7 mg/day for last 2 weeks), 5 sessions of brief behavioural smoking cessation treatment (in person and phone over 4 weeks, 20‐ 30 mins each)
Outcomes	Continuous abstinence at 12m Validation: salivary cotinine < 10 ng/ml
Notes	New for 2013. Significantly higher abstinence in 16 week arm than in 10 week arm, results presented separately in meta‐analysis with control divided. N abstinent not reported, extrapolated from percentages provided. Funding: American Cancer Society
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Urn randomization, no further detail provided
Allocation concealment (selection bias)	Unclear risk	Not specified
Blinding (performance bias and detection bias) All outcomes	High risk	Open‐label
Incomplete outcome data (attrition bias) All outcomes	Low risk	Over 90% followed up at 12m. Similar rates across arms.